Cancer Immunotherapy News and Research

RSS
First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

First patient treated in multicentre Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine for melanoma

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

NewLink Genetics reports positive data from Phase 2 trial of HyperAcute-Pancreas cancer immunotherapy

Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer

Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer

Epeius Biotechnologies announces Phase I/II study results of Rexin-G and Reximmune-C for cancer immunotherapy

Epeius Biotechnologies announces Phase I/II study results of Rexin-G and Reximmune-C for cancer immunotherapy

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

Update on CEL-SCI's Phase III clinical trial of Multikine

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy

Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy

Single dose of Pain Therapeutics' PTI-188 decreased  melanoma tumors: Study

Single dose of Pain Therapeutics' PTI-188 decreased melanoma tumors: Study

Epeius Biotechnologies' tumor-targeted vaccine technology for cancer immunotherapy receives patent protection

Epeius Biotechnologies' tumor-targeted vaccine technology for cancer immunotherapy receives patent protection

New anti-tumour vaccine for mesothelioma shows promising results

New anti-tumour vaccine for mesothelioma shows promising results

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Researchers demonstrate the safety of potential vaccine against mesothelioma

Researchers demonstrate the safety of potential vaccine against mesothelioma

Mentor Capital's Cancer Immunotherapy Index: First funding tranche to extend investment closes

Mentor Capital's Cancer Immunotherapy Index: First funding tranche to extend investment closes

Docking algorithm EADock allows successful design of new inhibitors for anti-cancer target

Docking algorithm EADock allows successful design of new inhibitors for anti-cancer target

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

3rd Annual OneMedForum to highlight therapeutic and diagnostic products for cancers

Protein marker may hold the key against pancreatic cancer

Protein marker may hold the key against pancreatic cancer

Bend Memorial Clinic to begin Phase III lung cancer trial

Bend Memorial Clinic to begin Phase III lung cancer trial

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.